New report singles out Big Pharma players for ringing their blockbusters with patents while hiking prices for years
What do Roche, Pfizer and AbbVie all have in common, aside from sharing Big Pharma status?
They all have pursued a strategy of padding their defense of blockbuster franchises with a bristling set of patents while steadily pushing up the price of their biggest earners.
That’s the conclusion of a nonprofit group called Initiative for Medicines, Access & Knowledge (I-MAK), which has issued a new report that spells out how this strategy works — at the expense of consumers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.